Randomized Pharmacokinetic Study of a Highly Purified Human Chorionic Gonadotropin and of a Recombinant Human Chorionic Gonadotropin Following Single Subcutaneous Administration in Healthy Women

What Was Tested

This randomized controlled trial paper looks at hCG (human chorionic gonadotropin).

Exogenous human chorionic gonadotropin (hCG) acts on the final phase of the follicle maturation.

Choriomon®, a highly purified hCG formulation, is approved in many European and extra-European countries for the induction of ovulation after stimulation of follicular development.

The present study compares hCG bioavailability of Choriomon® (Test product) versus a recombinant hCG preparation (Ovitrelle®; Reference product).

Who Took Part

The study group was 26 women.

PubMed tags the participants as women only.

How the Study Was Run

The design is described as randomized and crossover.

Random assignment meant chance, not the researchers, decided who got hCG (human chorionic gonadotropin) and who got the comparison, which limits bias.

Each person switched between hCG (human chorionic gonadotropin) and the comparison at some point, usually with a gap in between.

What Was Measured

PubMed files the paper under topics including Area Under Curve, Biological Availability, Chorionic Gonadotropin and Therapeutic Equivalency.

What This Means in Plain Language

The paper is a randomized and crossover study of hCG (human chorionic gonadotropin) in 26 women.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 7 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2022 (Clinical drug investigation), a journal based in New Zealand.

More context: the hCG (human chorionic gonadotropin) compound page, all human trials.